Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Timmerman

Showing results (201-210 of 229) with videos related to

Pageof 23
Sort By:
Cancer Research|March 20, 2019
An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1<sup>-</sup>HK2<sup>+</sup> Multiple MyelomaShili Xu, Tianyuan Zhou, Hanna M Doh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2019
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II StudyStephen M Ansell, Monique C Minnema, Peter Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 TrialPhilippe Armand, Andreas Engert, Anas Younes, et al.
Transplantation and Cellular Therapy|August 26, 2024
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell LymphomaFrederick L Locke, Sattva S Neelapu, Nancy L Bartlett, et al.
The New England Journal of Medicine|December 9, 2014
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphomaStephen M Ansell, Alexander M Lesokhin, Ivan Borrello, et al.
Science Signaling|October 12, 2021
Signaling by the inhibitory receptor CD200R is rewired by type I interferonMichiel van der Vlist, M Inês Pascoal Ramos, Lucas L van den Hoogen, et al.
The Lancet. Oncology|July 25, 2016
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trialAnas Younes, Armando Santoro, Margaret Shipp, et al.
Genome|September 26, 2007
Construction and characterization of two bacterial artificial chromosome libraries of pea (Pisum sativum L.) for the isolation of economically important genesC J Coyne, M T McClendon, J G Walling, et al.
Plos One|October 16, 2010
Identification of Mendel's white flower characterRoger P Hellens, Carol Moreau, Kui Lin-Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2012
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patientsSara A Hurvitz, David J Betting, Howard M Stern, et al.
Pageof 23

Showing results (201-210 of 229) with videos related to

Sort By:
Pageof 23
Cancer Research|March 20, 2019
An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1<sup>-</sup>HK2<sup>+</sup> Multiple MyelomaShili Xu, Tianyuan Zhou, Hanna M Doh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2019
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II StudyStephen M Ansell, Monique C Minnema, Peter Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 TrialPhilippe Armand, Andreas Engert, Anas Younes, et al.
Transplantation and Cellular Therapy|August 26, 2024
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell LymphomaFrederick L Locke, Sattva S Neelapu, Nancy L Bartlett, et al.
The New England Journal of Medicine|December 9, 2014
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphomaStephen M Ansell, Alexander M Lesokhin, Ivan Borrello, et al.
Science Signaling|October 12, 2021
Signaling by the inhibitory receptor CD200R is rewired by type I interferonMichiel van der Vlist, M Inês Pascoal Ramos, Lucas L van den Hoogen, et al.
The Lancet. Oncology|July 25, 2016
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trialAnas Younes, Armando Santoro, Margaret Shipp, et al.
Genome|September 26, 2007
Construction and characterization of two bacterial artificial chromosome libraries of pea (Pisum sativum L.) for the isolation of economically important genesC J Coyne, M T McClendon, J G Walling, et al.
Plos One|October 16, 2010
Identification of Mendel's white flower characterRoger P Hellens, Carol Moreau, Kui Lin-Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2012
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patientsSara A Hurvitz, David J Betting, Howard M Stern, et al.
Pageof 23